Kathryn Romano - Feb 28, 2024 Form 4 Insider Report for Krystal Biotech, Inc. (KRYS)

Signature
/s/ Kathryn Romano
Stock symbol
KRYS
Transactions as of
Feb 28, 2024
Transactions value $
-$889,034
Form type
4
Date filed
3/1/2024, 08:20 PM
Previous filing
Feb 28, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KRYS Common Stock Options Exercise $41.2K +648 +5.01% $63.55 13.6K Feb 28, 2024 Direct F1
transaction KRYS Common Stock Sale -$105K -648 -4.77% $162.71 12.9K Feb 28, 2024 Direct F1, F2
transaction KRYS Common Stock Options Exercise $57.2K +900 +6.96% $63.55 13.8K Feb 28, 2024 Direct F1
transaction KRYS Common Stock Sale -$147K -900 -6.5% $163.68 12.9K Feb 28, 2024 Direct F1, F3
transaction KRYS Common Stock Options Exercise $90.8K +1.43K +11.05% $63.55 14.4K Feb 28, 2024 Direct F1
transaction KRYS Common Stock Sale -$236K -1.43K -9.95% $164.81 12.9K Feb 28, 2024 Direct F1, F4
transaction KRYS Common Stock Options Exercise $19.1K +300 +2.32% $63.55 13.2K Feb 28, 2024 Direct F1
transaction KRYS Common Stock Sale -$49.8K -300 -2.27% $166.06 12.9K Feb 28, 2024 Direct F1, F5
transaction KRYS Common Stock Options Exercise $19.1K +300 +2.32% $63.55 13.2K Feb 28, 2024 Direct F1
transaction KRYS Common Stock Sale -$50.4K -300 -2.27% $167.85 12.9K Feb 28, 2024 Direct F1, F6
transaction KRYS Common Stock Options Exercise $77.3K +1.22K +9.4% $63.55 14.2K Feb 28, 2024 Direct F1
transaction KRYS Common Stock Sale -$206K -1.22K -8.59% $169.09 12.9K Feb 28, 2024 Direct F1, F7
transaction KRYS Common Stock Options Exercise $7.44K +117 +0.9% $63.55 13.1K Feb 28, 2024 Direct F1
transaction KRYS Common Stock Sale -$19.9K -117 -0.9% $169.82 12.9K Feb 28, 2024 Direct F1, F8
transaction KRYS Common Stock Options Exercise $5.72K +90 +0.7% $63.55 13K Feb 28, 2024 Direct F1
transaction KRYS Common Stock Sale -$15.5K -90 -0.69% $172.23 12.9K Feb 28, 2024 Direct F1
transaction KRYS Common Stock Options Exercise $0 +5K +38.65% $0.00 17.9K Feb 28, 2024 Direct F9
transaction KRYS Common Stock Tax liability -$377K -2.31K -12.9% $163.08 15.6K Feb 28, 2024 Direct F10, F11

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KRYS Stock Option (Right to Buy) Options Exercise $0 -5K -16.67% $0.00 25K Feb 28, 2024 Common Stock 5K $63.55 Direct F1, F12
transaction KRYS Performance Stock Units Options Exercise $0 -5K -50% $0.00 5K Feb 28, 2024 Common Stock 5K Direct F13, F14
transaction KRYS Performance Stock Units Award $0 +15K $0.00 15K Feb 29, 2024 Common Stock 15K Direct F15, F16, F17, F18
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on August 29, 2023 and will terminate on June 28, 2024 and contemplates option exercises and sales of 5,000 shares with a limit price of $150.00 per share.
F2 The transaction was executed in multiple trades ranging from $162.155 to $163.100. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F3 The transaction was executed in multiple trades ranging from $163.190 to $164.100. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F4 The transaction was executed in multiple trades ranging from $164.300 to $165.220. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F5 The transaction was executed in multiple trades ranging from $165.980 to $166.110. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F6 The transaction was executed in multiple trades ranging from$167.540 to $168.010. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F7 The transaction was executed in multiple trades ranging from $168.680 to $169.610. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F8 The transaction was executed in multiple trades ranging from $169.790 to $170.000. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F9 10,000 performance stock units ("PSUs") were granted on February 28, 2023. Each PSU represented a contingent right to receive one share of the Company's common stock, subject to the achievement of certain performance criteria during the year ended December 31 2023, as approved by the Company's Compensation Committee, and the Reporting Person's continued service to the Company on each applicable vesting date following such achievement. All of the performance criteria were achieved and one-half of the PSUs granted, or 5,000 PSUs, vested on February 28, 2024.
F10 Represents the number of shares of common stock surrendered to the Company for tax withholding upon the vesting of 5,000 PSUs on February 28, 2024.
F11 The closing price on February 28, 2024 of the Company's common stock on NASDAQ.
F12 50,000 options were granted that vest in four equal annual installments with the first installment vesting on February 28, 2023.
F13 Each PSU represented a contingent right to receive one share of the Company's common stock, subject to the achievement of certain performance criteria during the year ended December 31, 2023, as approved by the Company's Compensation Committee, and the Reporting Person's continued service to the Company on each applicable vesting date following such achievement. All of the performance criteria were achieved and one-half of the PSUs granted, or 5,000 PSUs, vested on February 28, 2024.
F14 The Performance Stock Units vest ratably over a two-year period with the first installment vesting on February 28, 2024.
F15 Each PSU represents a contingent right to receive one share of the Company's common stock, subject to the achievement of certain performance criteria during the year ended December 31, 2024, as approved by the Company's Compensation Committee, and the Reporting Person's continued service to the Company on each applicable vesting date following such achievement.
F16 The number of PSUs in this column represents the number of shares of common stock the Reporting Person will receive assuming achievement of all of the performance criteria set by the Company's Compensation Committee for this PSU award and full vesting.
F17 If any applicable portion of the performance criteria have been achieved, the PSU award shall vest in two equal annual installments (February 28, 2025 and February 28, 2026).
F18 If some or all of the performance criteria are not achieved, the applicable portion of the PSU award will be forfeited.